Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.
Last trade$27.89
Day change-$1.87 (-6.28%)
Day range$27.12 – $30.05
Volume254,281
Market cap$1.32B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$1.32B
Price / earnings
—
Price / book
3.58×
Price / sales
—
EV / sales
—
EV / EBITDA
-10.18×
Profitability
Earnings per share
-$2.45
Return on assets
-27.31%
Return on equity
-29.45%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.04×
Current ratio
25.76×
Quick ratio
25.76×
Cash ratio
11.23×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$100.29M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for AVLN, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Revenue
$0
$0
Cost of revenue
$0
$0
Gross profit
$0
$0
Selling, general and administrative
$7.6M
$6.56M
Research and development
$25.49M
$24.73M
Total operating expenses
$33.09M
$31.29M
Operating income
-$33.09M
-$31.29M
Interest expense
-$277K
-$272K
Income before taxes
-$29.66M
-$28.94M
Income taxes
$0
$0
Net income
-$29.66M
-$28.94M
Net income attributable to common shareholders
-$29.66M
-$28.94M
EBITDA
-$32.99M
-$31.18M
Basic earnings per share
-$0.67
-$0.98
Diluted earnings per share
-$0.67
-$0.98
Recent news
Company coverage with links to the original publishers.
Avalyn Pharma announced two poster presentations at the European Respiratory Society International Congress 2026 in Barcelona. The presentations will cover patient perspectives on IPF clinical trial participation and in silico modeling of AP01, the company's nebulized pirfenidone formulation. Avalyn has completed enrollment of its Phase 2b MIST trial with 398 patients, with topline data expected in the second half of 2027.
Avalyn Pharma announced completion of target enrollment of 375 patients in the Phase 2b MIST clinical trial of AP01 (inhaled pirfenidone) for progressive pulmonary fibrosis. The global, randomized, double-blinded, placebo-controlled trial is evaluating two doses of AP01 against placebo, with primary endpoint measuring change in lung function at 52 weeks. Topline data is expected in the second half of 2027.
Avalyn Pharma, a clinical-stage biopharmaceutical company, announced Q1 2026 financial results and pipeline updates following its May 2026 IPO that raised $345 million in gross proceeds. The company is on track to complete enrollment of its MIST Phase 2b trial of AP01 (inhaled pirfenidone) for progressive pulmonary fibrosis by mid-2026, with topline data expected in H2 2027. Long-term open-label extension data presented at EULAR showed favorable tolerability over four years. AP02 (inhaled nintedanib) enrollment is underway in the AURA Phase 2 trial with results anticipated by end of 2027. The company projects its cash position of $123.1 million plus $316.1 million in IPO proceeds will fund operations into 2029.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.